Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study.
Cornberg M, Ahumada A, Aghemo A, Andreoni M, Bhagat A, Butrymowicz I, Carmiel M, Chodick G, Conway B, Song Y, Gasbarrini A, Hüppe D, Plaza FJ, Lampertico P, Alonso MLM, Myles L, Persico M, Ramji A, Sarrazin C, Villa E, Weil C, Otano JIU; CREST Study Group.
Cornberg M, et al. Among authors: alonso mlm.
Adv Ther. 2022 Jul;39(7):3146-3158. doi: 10.1007/s12325-022-02158-6. Epub 2022 May 11.
Adv Ther. 2022.
PMID: 35543964
Free PMC article.